Biomarker ID | 1725 |
PMID | 30777394 |
Year | 2019 |
Biomarker | miR-24+miR-30c+ Methylation Status of CRIP3 |
Biomarker Basis | Expression Based+ Methylation Based |
Biomolecule | miRNA + DNA (Gene) |
Source | Urine |
Subjects | Humans |
Regulation | Increased in shorter BCR-free survival |
Odds Ratio/Hazard Ratio/Relative Risk | OR: Univariate: 2.166 (95% CI: 1.22-3.847); Multivariate: 1.992 (95% CI: 1.131-3.51) |
Effect on Pathways | Pathway include: KRAS pathway |
Experiment | Reclassification (Progression Vs No Progression) |
Type of Biomarker | Prognostic |
Cohort | 109 patients with Prostate Cancer were selected for the study. Out of which 23 patients were reclassified: |
Senstivity | 81% |
Specificity | 59.7% |
AUC | 0.708 (95% CI: 0.586-0.830) |
Accuracy | NA |
Level Of Significance | Univariate: p=0.008; Multivariate: p=0.017 |
Method Used | qPCR-based MethyLight assay |
Clinical | No |
Remarks | Patients were considered reclassified if they experienced Gleason Grade increase on repeat biopsy |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |